|
|
| | Raloxifene-d10 Basic information |
| Product Name: | Raloxifene-d10 | | Synonyms: | [4-[2-(2,2,3,3,4,4,5,5,6,6-decadeuteriopiperidin-1-yl)ethoxy]phenyl]-[6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]methanone;Raloxifene-d10-1 | | CAS: | 2512224-37-0 | | MF: | C28H17D10NO4S | | MW: | 483.65 | | EINECS: | | | Product Categories: | | | Mol File: | 2512224-37-0.mol |  |
| | Raloxifene-d10 Chemical Properties |
| Boiling point | 728.193±60.00 °C(Press: 760.00 Torr)(predicted) | | density | 1.289±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) |
| | Raloxifene-d10 Usage And Synthesis |
| Uses | Raloxifene-d10-1 is the deuterium labeled Raloxifene[1]. Raloxifene (Keoxifene) is a benzothiophene-derived selective estrogen receptor modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research[2]. | | References | [1] Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. DOI:10.1177/1060028018797110
[2] Khovidhunkit W, et al. Clinical effects of raloxifene hydrochloride in women. Ann Intern Med. 1999;130(5):431-439. DOI:10.7326/0003-4819-130-5-199903020-00015
[3] Xu H, et al. Effect of caffeine on ovariectomy-induced osteoporosis in rats. Biomed Pharmacother. 2019112:108650. DOI:10.1016/j.biopha.2019.108650 |
| | Raloxifene-d10 Preparation Products And Raw materials |
|